0.2249
12.68%
+0.0253
시장 영업 전:
.232
0.0071
+3.16%
Cns Pharmaceuticals Inc 주식(CNSP)의 최신 뉴스
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results - Yahoo Canada Finance
Yahoo Canada Finance
CNS Specific Antisense Oligonucleotides Market 2023 Trends with Analysis on Key Players Akcea Therapeutics, Inc ... - Amoré
Amoré
CNSP: Riding the Market Waves of Growth and Decline in 2023 – Invest Chronicle - The InvestChronicle
The InvestChronicle
Investing in Cns Pharmaceuticals Inc (CNSP): What You Must Know – Knox Daily - Knox Daily
Knox Daily
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing ... - Yahoo Finance
Yahoo Finance
CNS Pharmaceuticals to Present at the LSX World Congress 2024 - Yahoo Finance
Yahoo Finance
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK ... - Yahoo Finance
Yahoo Finance
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical ... - Yahoo Finance
Yahoo Finance
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day - Business Wire
Business Wire
Xenon Pharmaceuticals Engages at Stifel CNS Event - TipRanks.com - TipRanks
TipRanks
Avadel Told To Pay Jazz Pharma $234K Over Narcolepsy Drug IP - Law360
Law360
CNS Pharmaceuticals Strives to Regain Nasdaq Compliance - TipRanks.com - TipRanks
TipRanks
Gene and Cell Therapies Targeting CNS Disorders Market is Predicted to Exhibit Remarkable Growth by 2032 ... - GlobeNewswire
GlobeNewswire
Top 5 Health Care Stocks That Are Preparing To Pump In February
Benzinga
Top 5 Health Care Stocks That Are Preparing To Pump In February - CNS Pharma (NASDAQ:CNSP), Biolase (NASD - Benzinga
Benzinga
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Benzinga
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering - Yahoo Finance
Yahoo Finance
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors - Yahoo Finance
Yahoo Finance
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc ... - Yahoo Finance
Yahoo Finance
Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS ... - Yahoo Finance
Yahoo Finance
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant - Yahoo Finance
Yahoo Finance
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of ... - Yahoo Finance
Yahoo Finance
Global CNS Therapeutics Strategic Report 2023: Market to Reach $199 Billion by 2030 - Developing Market to Drive ... - Yahoo Finance
Yahoo Finance
AiBtl signs $667m licensing deal for ABVC’s CNS drug - Pharmaceutical Technology
Pharmaceutical Technology
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ... - GlobeNewswire
GlobeNewswire
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer - Business Wire
Business Wire
SK Biopharm eyes Asia's No.1 spot in radioactive drug market - Korea Economic Daily
Korea Economic Daily
Busting the Brain's Firewall: How Lantern Pharma's Algorithms Can Predict a Drug's Ability to Reach the Brain - dallasinnovates.com
dallasinnovates.com
JOANN And 3 Other Stocks Under $4 Insiders Are Aggressively Buying - Avalo Therapeutics (NASDAQ:AVTX), CNS ... - Benzinga
Benzinga
CNS Pharmaceuticals enrols over 100 subjects for GBM trial - Clinical Trials Arena
Clinical Trials Arena
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company ... - GlobeNewswire
GlobeNewswire
Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as ... - Business Wire
Business Wire
Federal Circuit Affirms Jazz Pharmaceutical's Risk Evaluation and Mitigation Strategy Patent Is Not Listable in Orange ... - Wilson Sonsini
Wilson Sonsini
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the ... - PR Newswire
PR Newswire
Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central ... - Business Wire
Business Wire
Jazz Pharma ruling clears U.S. roadblock for rival narcolepsy drug - Reuters
Reuters
CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical ... - PR Newswire
PR Newswire
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer - PR Newswire
PR Newswire
CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event - PR Newswire
PR Newswire
CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors - PR Newswire
PR Newswire
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for ... - PR Newswire
PR Newswire
SciNeuro Pharmaceuticals Announces the Appointment of Guojun Bu, Ph.D., as Chief Scientific Officer, and Provides ... - PR Newswire
PR Newswire
CNS Pharmaceuticals Announces Reverse Stock Split - PR Newswire
PR Newswire
Glioblastoma Multiforme Treatment Market Size to Hit $10.2 BN By 2030 - BioSpace
BioSpace
CNS doses first subject in brain cancer treatment trial in France - Clinical Trials Arena
Clinical Trials Arena
CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update - BioSpace
BioSpace
Glioma Pipeline Insights | Clinical Trial Research Evaluation Report By DelveInsight - PR Newswire
PR Newswire
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global ... - PR Newswire
PR Newswire
CNS to commence study of Berubicin for glioblastoma multiforme - Clinical Trials Arena
Clinical Trials Arena
자본화:
|
볼륨(24시간):